Skip to main content

Table 3 Summary of results from studies reporting anti-HCV prevalence in MSM and prisoner

From: Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update

Author, year Country Recruiting period Population as reported Age, mean (SD) Sample size Anti-HCV prevalence (%) (95% CI) Risk of selection bias
MSM
 Ireland, 2017 [39] UK 28 February - 15 December 2014 MSM attending 4 genitourinary medicine clinics in Manchester HIV+:735
HIV-:855
1.80 (−)
0.20 (−)
Low risk
 Vanhommerig, 2013 [40] Netherland 2009–2012 HIV-infected MSM during 5 waves of anonymous surveys at Amsterdam STI clinic 439 7.10 (−) High risk
 Cotte, 2018 [41] France January 2016 to May 2017 HIV+, HCV-negative MSM with serological follow-up in 2016 HIV+:13051
HIV-:930
5.10 (−)
1.80 (−)
Low risk
Prisoner
 Ekeke, 2018 [42] UK December 2015-February 2017 Prisoners entered Pentonville prison 1324 7.00 (−) High risk
 Patel, 2016 [43] UK Inmates in a medium security prison 160 33.75 (−) High risk
 Casella, 2016 [44] Portugal 2014 and 2016 Inmates of 2 male prisons in the centre of Portugal (Pinheiro da Cruz and Setubal) 82 38.00 (−) High risk
 Liberal, 2017 [45] Portugal January–April Inmates from one of the largest prisons in Portugal 1208 15.70* (−) High risk
 Svendsen, 2017 [46] Norway September 2015 At-risk populations in Trondheim, Norway 304 41.00 (−) High risk
 Lerena, 2016 [47] Spain Inmates in a Northern region of Spain
(Cantabria) with 600 k inhabitants and focused on the regional long-stay prison of El Dueso
436 16.00 (−) High risk